JP2011157350A - Liquid composition - Google Patents

Liquid composition Download PDF

Info

Publication number
JP2011157350A
JP2011157350A JP2011001498A JP2011001498A JP2011157350A JP 2011157350 A JP2011157350 A JP 2011157350A JP 2011001498 A JP2011001498 A JP 2011001498A JP 2011001498 A JP2011001498 A JP 2011001498A JP 2011157350 A JP2011157350 A JP 2011157350A
Authority
JP
Japan
Prior art keywords
bamboo vinegar
liquid composition
vinegar
benzpyrene
bamboo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011001498A
Other languages
Japanese (ja)
Other versions
JP4920788B2 (en
Inventor
Yasuhiro Takano
康博 高野
Ken Hosoya
憲 細矢
Keita Kato
啓大 加藤
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to JP2011001498A priority Critical patent/JP4920788B2/en
Publication of JP2011157350A publication Critical patent/JP2011157350A/en
Application granted granted Critical
Publication of JP4920788B2 publication Critical patent/JP4920788B2/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide therapeutic agents for diabetes, hemorrhoids, trichophytosis unguium, colon polyps and the like. <P>SOLUTION: A liquid composition is prepared by impregnating absorbent cotton having about 1 cm×1 cm size with wood vinegar (e.g. bamboo vinegar) containing ≤1 ppt weight benzopyrene and is used by inserting the same into the anus. Thereby, the bactericidal action inherited to the bamboo vinegar is directly acted to the affected part, as well as imparts bactericidal function to blood flow through inner organs such as liver and expresses bactericidal effects from the internal organs and the insides of peripheral parts of the body to be able to improve symptoms such as trichophytosis unguium and colon polyps. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

本発明は、竹酢液などの木酢液が有する殺菌力やインスリン受容体の抗体の消滅作用を用いた、糖尿病、痔、爪水虫、大腸ポリープなどの治療剤としての用途に有用な木酢液に関するものである。   The present invention relates to a wood vinegar solution useful for use as a therapeutic agent for diabetes, hemorrhoids, nail fungus, colon polyps, etc., using the bactericidal power of wood vinegar solution such as bamboo vinegar and the annihilation action of antibodies of insulin receptor. Is.

木酢液は木材を乾留した際に生じる乾留液の上澄分のことであり。代表的な例としては、炭焼き時に副産物として木酢液が製造される。なお、本明細書においては、木材としては、竹、松などの一般的な木材のみならず、椿科植物などの花をも含む植物一般を意味するものとする。
木材が竹である竹酢液は、乾留によって竹炭を製造する際に発生する液体成分であり、約90%(重量%、以下同じ)が水、約5%が酢酸で、その他にアルコ一ル類、エステル類、フェノール類など約200種類もの有機機成分が含まれている。
Wood vinegar is the supernatant of dry-distilled liquid that is produced when wood is carbonized. As a typical example, wood vinegar is produced as a by-product during charcoal baking. In the present specification, wood means not only general wood such as bamboo and pine but also general plants including flowers such as vines.
Bamboo vinegar, which is made from bamboo, is a liquid component that is generated when bamboo charcoal is produced by dry distillation. About 90% (% by weight, the same shall apply hereinafter) is water, about 5% is acetic acid, and other alcohol. About 200 kinds of organic machine components such as alcohols, esters and phenols are included.

その他に、竹酢液に含まれる、酢酸や有機酸の化合物の殺菌作用を利用した用途の例として、特許文献1には、竹酢液を含むクリーム状組成物を患部に塗布することにより、アトピー性皮膚炎や爪水虫の治療剤として、効果を奏することが開示されている。   In addition, as an example of the application using the bactericidal action of acetic acid and organic acid compounds contained in bamboo vinegar, Patent Document 1 includes applying a cream-like composition containing bamboo vinegar to the affected area. It has been disclosed that it is effective as a therapeutic agent for atopic dermatitis and nail fungus.

また、特許文献2には、発がん性物質であるベンツピレンを除去した竹酢液を、飲食物に添加して経口摂取することにより、動脈硬化、糖尿病、花粉症に対して、治療効果や症状の改善の効果が得られることが開示されている。   Patent Document 2 discloses that a bamboo vinegar solution from which benzpyrene, which is a carcinogenic substance, has been removed is added to food and drink and orally ingested, so that therapeutic effects and symptoms of arteriosclerosis, diabetes, and hay fever are obtained. It is disclosed that an improvement effect can be obtained.

前記の他にも、薬剤を経口投与することにより、様々な疾病に対処する化学療法が行なわれているが、これらは大腸の状態を正常にし、ウイルスなどの感染による受容体に抗体が生成される作用を改善し、生体の新陳代謝を旺盛にして、生体各部の機能を正常化することを目的とした改善法である。   In addition to the above, chemotherapy to deal with various diseases by oral administration of drugs is performed, but these normalize the state of the large intestine, and antibodies are generated at receptors due to infection such as viruses. This is an improvement method aimed at normalizing the functions of each part of the living body by improving the action of the living body and increasing the metabolism of the living body.

しかしながら、前記の薬剤投与法は経口投与であるため、直接患部あるいは粘膜に作用することが少ない。そのため、ベンツピレンの濃度についてもその濃度は厳しく規定されているわけではない。たとえば、特許文献2では、『発ガン性物質であるベンツピレンなどの有害物質の混入がなく、非常に安全性の高い竹酢液』とされているが、ベンツピレンの具体的な濃度の記載はなく、実際のベンツピレンの濃度は、数十1pptをはるかに超えている。   However, since the above-mentioned drug administration method is oral administration, it hardly affects the affected area or mucous membrane directly. Therefore, the concentration of benzpyrene is not strictly regulated. For example, Patent Document 2 states that “bamboo vinegar is extremely safe without the inclusion of harmful substances such as benzpyrene, which is a carcinogenic substance,” but there is no specific concentration of benzpyrene. The actual concentration of benzpyrene is well over several tens of ppt.

肛門から投与する場合には、経口あるいは外皮からの投与とは異なり、組成物は、直接患部乃至粘膜に作用するため副作用成分であるベンツピレンの含有量は極力低減させる必要がある。しかるに、現在のところ、ベンツピレンを1ppt以下とした技術は提示されていない。   When administered from the anus, unlike the oral or epidermal administration, the composition acts directly on the affected area or mucous membrane, so the content of benzpyrene, which is a side effect component, must be reduced as much as possible. However, at the present time, no technology has been proposed in which Benzpyrene is set to 1 ppt or less.

特開2005−200393号公報Japanese Patent Laid-Open No. 2005-200393 特開2004−141141号公報JP 2004-141141 A

従って、本発明の課題は、副作用が極めて少ない安価な天然素材であり人体に安全性のある木酢液を用いて、家庭でも実施可能な、糖尿病、痔、爪水虫、大腸ポリープなどの治療効果を発揮することが可能な液状組成物を提供することにある。   Therefore, an object of the present invention is to provide a therapeutic effect for diabetes, hemorrhoids, nail fungus, colon polyps, etc. that can be carried out at home using a natural vinegar solution that is an inexpensive natural material with extremely few side effects and is safe for the human body. It is providing the liquid composition which can be exhibited.

請求項1に係る発明は、ベンツピレンの含有量が1ppt(重量ppt、以下同じ)以下の木酢液からなり、肛門から投与して用いることを特徴とする液状組成物である。   The invention according to claim 1 is a liquid composition characterized in that the content of benzpyrene consists of a wood vinegar solution of 1 ppt (weight ppt, the same shall apply hereinafter) or less and is administered through the anus.

請求項2に係る発明は、大腸内の回虫、ヘリコバクター・ピロリを死滅させるとともに、インスリン受容体の抗体を消滅させる糖尿病治療剤としての用途に用いる請求項1記載の液状組成物である。
請求項3に係る発明は、木酢液の殺菌作用を、直接患部に作用させる痔の治療剤としての用途に用いる請求項1記載の液状組成物である。
請求項4に係る発明は、木酢液の殺菌作用を、門脈を通過せず血流に付与する爪水虫又は大腸ポリープの治療剤としての用途に用いる請求項1記載の液状組成物である。
請求項5に係る発明は、木酢液は竹酢液である請求項1ないし4のいずれか1項記載の液状組成物である。
The invention according to claim 2 is the liquid composition according to claim 1, which is used as a therapeutic agent for diabetes that kills roundworms and Helicobacter pylori in the large intestine and extinguishes insulin receptor antibodies.
Invention of Claim 3 is a liquid composition of Claim 1 used for the use as a therapeutic agent of the hemorrhoid which makes the bactericidal action of a wood vinegar liquid act on an affected part directly.
The invention according to claim 4 is the liquid composition according to claim 1, which is used as a therapeutic agent for nail athlete's foot or colon polyp which imparts the bactericidal action of wood vinegar to the bloodstream without passing through the portal vein.
The invention according to claim 5 is the liquid composition according to any one of claims 1 to 4, wherein the wood vinegar is bamboo vinegar.

本発明は、前記のように、木酢液に浸した綿を肛門に挿入して、殺菌作用などを有する竹酢液の有効成分を、患部に直接投与する他、直腸から吸収された後、肝臓を経由して全身の血流に付与する方法なので、従来の治療方法では得られなかった優れた効果を奏する。   As described above, the present invention inserts cotton soaked in wood vinegar into the anus and administers the active ingredient of bamboo vinegar having bactericidal action directly to the affected area, and after being absorbed from the rectum, the liver Since it is a method of giving to the blood flow of the whole body via the, it has an excellent effect that could not be obtained by conventional treatment methods.

また、患者自身が使用可能であることや、副作用が少ないことから、近年の食生活の欧来化による成人病の増加や、それによって増加する患者の経済的な負担、深刻化する医師不足などの諸問題にも対処することができる。   In addition, because patients can use themselves and there are few side effects, there is an increase in adult diseases due to the recent shift to dietary habits in Europe, the increasing economic burden on patients, and the growing shortage of doctors. It is possible to deal with these problems.

具体的には、竹酔液あるいは木酢液の殺菌機能が、痔の患部には直接作用し、爪水虫や大腸ポリープには血流を介して作用する。
また、胃炎や胃・十二指腸潰瘍などの消化性潰瘍の原因と考えられていたヘリコバクター・ピロリが、血糖値を下げるインスリンの働きを妨害する抗体を自分でつくってしまう、B型インスリン抵抗症という糖尿病の原因となっていたことが近年明らかとなっているが、竹酔液あるいは木酢液の殺菌作用は、ヘリコバクター・ピロリを死滅させることにも有効であり、ひいてはB型インスリン抵抗症にも治療効果がある。
ベンツピレンが1ppt以下であるため、これに起因する発がんなどの副作用を考慮する必要なく上記治療剤として用いることができる。
Specifically, the sterilization function of bamboo drunk or pyroligneous acid acts directly on the affected area of the heel and acts on the nail athlete's foot and colon polyps via the bloodstream.
Diabetes type B insulin resistance, in which Helicobacter pylori, which was thought to cause peptic ulcers such as gastritis and gastric / duodenal ulcers, creates antibodies that interfere with the action of insulin that lowers blood glucose level In recent years, it has been clarified that the sterilization effect of bamboo drunk or pyroligneous acid is effective in killing Helicobacter pylori, and also has therapeutic effects on B-type insulin resistance. There is.
Since benzpyrene is 1 ppt or less, it can be used as the therapeutic agent without having to consider side effects such as carcinogenesis caused by this.

竹酔液投与前の爪永虫の状態を撮影した写真である。It is the photograph which image | photographed the state of the nail moth before administration of bamboo drunk. 竹酢液を4ヶ月問繕続投尊した後の爪水虫の状態を撮影した写真である。This is a photograph of the condition of the nail fungus after the bamboo vinegar solution has been repaired for 4 months. 竹酢液を9ヶ月間継続投与した後の爪水虫の状態を撮影した写真である。It is the photograph which image | photographed the state of the nail athlete's foot after continuously administering bamboo vinegar for 9 months. 液体クロマトグラフィーシステムの概念図である。1 is a conceptual diagram of a liquid chromatography system. カラム法による竹酢液精製システムの概略図である。It is the schematic of the bamboo vinegar liquid refinement | purification system by the column method. 竹酢液の精製前後における外観写真である。It is an external appearance photograph before and after refinement | purification of a bamboo vinegar liquid. 精製後の竹酢液サンプルCの液体クロマトグラムである。It is a liquid chromatogram of the bamboo vinegar liquid sample C after refinement | purification. 竹酢液サンプルCのODSシリカ精製前後のGC−MSクロマトグラム図であり、(A)は精製前、(B)は精製後を示す。It is a GC-MS chromatogram before and after ODS silica purification of bamboo vinegar sample C, (A) shows before purification and (B) shows after purification. 実施例における竹酢液適用前における腸の内視鏡写真である。It is an endoscopic photograph of the intestine before bamboo vinegar application in an Example. 図9における検査部を示す腸の概念図である。FIG. 10 is a conceptual diagram of the intestine showing the examination unit in FIG. 9. 実施例における竹酢液適用後における腸の内視鏡写真である。It is an endoscopic photograph of the intestine after bamboo vinegar application in an Example. 図10における検査部を示す腸の概念図である。It is a conceptual diagram of the intestine which shows the test | inspection part in FIG.

次に本発明の実施の形態について説明する。
市販の竹酢液を3種類用意した。ベンツピレン濃度は次の通りである。
サンプルA:多量
サンプルB:10ppb(10μg/L)
サンプルC:60ppt(60ng/L)
ベンツピレンの濃度は、図4に示す液体クロマトグラフィーシステムを用いて分析した。
より詳細な分析装置、分析条件は次の通りである。
(分析装置)
送液ポンプ:LC−20AD (島津製作所)
オートサンプラー:SIL−20A/20AC (島津製作所)
カラムオーブン:CTO−20A/20AC(島津製作所)
検出器:RF−20A (島津製作所)
Next, an embodiment of the present invention will be described.
Three types of commercially available bamboo vinegar were prepared. The concentration of benzpyrene is as follows.
Sample A: Large amount Sample B: 10 ppb (10 μg / L)
Sample C: 60 ppt (60 ng / L)
The concentration of benzpyrene was analyzed using the liquid chromatography system shown in FIG.
A more detailed analysis apparatus and analysis conditions are as follows.
(Analysis equipment)
Liquid feed pump: LC-20AD (Shimadzu Corporation)
Autosampler: SIL-20A / 20AC (Shimadzu Corporation)
Column oven: CTO-20A / 20AC (Shimadzu Corporation)
Detector: RF-20A (Shimadzu Corporation)

(分析条件)
分析カラム:VP−ODS(150mmx4.6mmi.d.)
移動相:アセトニトリル/10mMリン酸緩衝液=8/2
流速:0.8 mL/min, Isocratic mode
評価温度:40℃
検出:蛍光検出、励起波長−295nm、蛍光波長−403nm

上記サンプルA、B、Cについて以下に述べる試薬を用い、以下の操作により竹酢液中のベンツピレンの除去を行った。
(試薬)
・アセトニトリル(和光純薬工業)
・メタノール(和光純薬工業)
・純水(Milli−Q 純水製造装置)
・ODSシリカ(Cosmosil 140C18−0PN、ナカライテスク)
※評価に用いたODSシリカ(オクタデシル基結合型シリカゲル)は平均粒径が140μmである。その表面は親水となっている。このODSシリカはオープンカラムにて使用できる。
(Analysis conditions)
Analysis column: VP-ODS (150 mm × 4.6 mm.d.)
Mobile phase: acetonitrile / 10 mM phosphate buffer = 8/2
Flow rate: 0.8 mL / min, Isocratic mode
Evaluation temperature: 40 ° C
Detection: fluorescence detection, excitation wavelength -295 nm, fluorescence wavelength -403 nm

Benzpyrene in bamboo vinegar was removed by the following operations using the reagents described below for Samples A, B, and C.
(reagent)
・ Acetonitrile (Wako Pure Chemical Industries)
・ Methanol (Wako Pure Chemical Industries)
・ Pure water (Milli-Q pure water production equipment)
· ODS silica (Cosmosil 140C 18 -0PN, Nacalai Tesque)
* ODS silica (octadecyl group-bonded silica gel) used for evaluation has an average particle size of 140 μm. Its surface is hydrophilic. This ODS silica can be used in an open column.

(操作)
図5にカラム法による竹酢液精製手順の概念を示す。
1)30%アセトニトリル水溶液、100mL中にODSシリカ20gを分散させスラリーとした。
2)脱脂綿、海砂を一端に充てんした内径25mmのガラスカラムに、上記スラリーを充填した。
3)コンディショニングとして、メタノール、水を各100mL通液し、ODSシリカを活性化した。
4)市販竹酢液サンプルA、B、Cを各100mL通液し、通過液を回収した。
5)回収液中のベンツピレン濃度を測定するため、液体クロマトグラフィー一蛍光検出により、各回収液を分析した。
(operation)
The concept of the bamboo vinegar liquid refinement | purification procedure by the column method is shown in FIG.
1) A slurry was prepared by dispersing 20 g of ODS silica in 100 mL of a 30% acetonitrile aqueous solution.
2) The slurry was filled in a glass column with an inner diameter of 25 mm filled with absorbent cotton and sea sand at one end.
3) As conditioning, 100 mL each of methanol and water were passed to activate ODS silica.
4) Commercially available bamboo vinegar liquid samples A, B, and C were passed through 100 mL each, and the passing liquid was collected.
5) In order to measure the concentration of benzpyrene in the recovered liquid, each recovered liquid was analyzed by liquid chromatography / fluorescence detection.

(分析結果)
・可視的変化
精製前後におけるサンプルの可視的な変化として、竹酢液サンプルAの精製前後の様子を図6に示す。これらの写真から明らかなように、精製前後において、タール成分由来の着色がほぼ完全に除去されていることが分かる。同様に、竹酢液特有の燻臭もほぼ消失していた。このことから、ベンツピレンを含むタール成分等が効率よく除去された。
・pH変化
精製処理前後における酸性度の評価について、すべてのサンプルにおいて精製前後でのpH変化は見られなかった。例えば、市販竹酢液サンプルAでは、精製前のpHが2.62であったのに対して、精製後では2.65となった。この結果が意味するところは、精製前後において主要成分である酢酸を含む有機酸成分は除去されておらず、抗菌性を有する有機酸の残存が示唆されている。
・液体クロマトグラフィー
精製後の市販竹酢液サンプルCの最終のクロマトグラムを図7に示す。この図の通り、ベンツピレンのピークは確認できず、ODSシリカのカラム法により、竹酢液中のベンツピレンは1ppt以下まで低減されている。
また、再現性評価についても、市販竹酢液サンプルCの繰り返し実験を行った結果、いずれのサンプルでもベンツピレンは確認されず、本法の再現性が良好であると判断できる。

・ベンツピレン以外の成分
ベンツピレン以外の成分についても分析を行った。
分析条件は次の通りである。
分析条件
GC−MS装置 : Agilent 5973
Vent−free GC/MS adaptor使用
キャピラリーカラム : UA5−15M−0.25F (5%polydiphenylsiloxane)
(15m、 0.25mmi.d.、0.25micron)
サンプル注入量 : 1μL
インジェクター : Split/split less injector−300℃、split ratio: 1/30
GC/MS interface : 300℃
MSイオン源 : 250℃
図8にサンプルCについて精製前後におけるGC−MSクロマトグラム分析結果を示す。
図8からわかるように、市販竹酢液サンプルCに含まれるブチルアクトン、フェノール系、グアイアコール、シリンゴール等が完全に除去されている。一方、酢酸を主成分とするl分付近の非常に大きなピークはほとんど変化していないことから、ODSシリカ処理によって、ベンツピレンのみではなく、同じく毒性を有する芳香族系化合物も除去されていることが明らかとなった。
確認のために、精製後の竹酢液中に含まれる多環芳香族類を高感度GC−MSを用いて評価した。評価に用いたのは、市販竹酢液サンプルCの未精製サンプルとそのODSシリカ精製品(カラム法)である。詳細な分析の結果、未精製の竹酢液サンプルCでは、上記蛍光分析と同じく、数十pptのベンツピレンが確認された。一方、 ODSシリカ精製後のサンプルでは、ベンツピレンを含む主要な多環芳香族類は全く検出されなかった。これらの結果から、他の分析法においてもベンツピレン除去が証明され、ODSシリカを用いたカラム法により1ppt未満に低減させた竹酢液を作成することができた。
(result of analysis)
-Visible change As a visible change of the sample before and after purification, the state before and after purification of the bamboo vinegar sample A is shown in FIG. As is apparent from these photographs, it can be seen that the coloration derived from the tar component is almost completely removed before and after purification. Similarly, the odor peculiar to bamboo vinegar has almost disappeared. From this, tar components and the like containing benzpyrene were efficiently removed.
-Regarding the evaluation of the acidity before and after the pH change purification treatment, no pH change was observed before and after purification in all samples. For example, in the commercially available bamboo vinegar liquid sample A, the pH before purification was 2.62, whereas it was 2.65 after purification. This result means that the organic acid component containing acetic acid, which is the main component, is not removed before and after purification, suggesting that an organic acid having antibacterial properties remains.
-Liquid chromatography The final chromatogram of the commercially available bamboo vinegar sample C after purification is shown in FIG. As shown in this figure, the peak of benzpyrene cannot be confirmed, and benzpyrene in the bamboo vinegar is reduced to 1 ppt or less by the ODS silica column method.
Moreover, about reproducibility evaluation, as a result of repeating experiment of the commercially available bamboo vinegar liquid sample C, benzpyrene is not confirmed by any sample, and it can be judged that the reproducibility of this method is favorable.

-Components other than Benzpyrene Components other than Benzpyrene were also analyzed.
The analysis conditions are as follows.
Analysis conditions GC-MS apparatus: Agilent 5973
Capillary column using Vent-free GC / MS adapter: UA5-15M-0.25F (5% polydiphenylsiloxane)
(15m, 0.25mm, 0.25micron)
Sample injection volume: 1 μL
Injector: Split / split less injector-300 ° C., split ratio: 1/30
GC / MS interface: 300 ° C
MS ion source: 250 ° C
FIG. 8 shows the results of GC-MS chromatogram analysis of sample C before and after purification.
As can be seen from FIG. 8, butylactone, phenolic, guaiacol, syringol and the like contained in the commercially available bamboo vinegar liquid sample C are completely removed. On the other hand, since a very large peak in the vicinity of 1 minute containing acetic acid as a main component is hardly changed, not only benzpyrene but also an aromatic compound having the same toxicity is removed by the ODS silica treatment. It became clear.
For confirmation, polycyclic aromatics contained in the purified bamboo vinegar solution were evaluated using high-sensitivity GC-MS. An unpurified sample of commercially available bamboo vinegar liquid sample C and its ODS silica purified product (column method) were used for evaluation. As a result of detailed analysis, in the unpurified bamboo vinegar sample C, tens pyrt of tens of ppt was confirmed as in the fluorescence analysis. On the other hand, in the sample after purification of ODS silica, no major polycyclic aromatics including benzpyrene were detected at all. From these results, benzpyrene removal was proved also in other analysis methods, and a bamboo vinegar solution reduced to less than 1 ppt by a column method using ODS silica could be prepared.

(投与試験)
上記手順により精製を行った竹酢液について人への投与試験を行った。
用いた竹酢液は上述したサンプルCを精製してベンツピレン濃度を1ppt以下としたものである。
本例の竹酢液の使用方法は、前記のように、脱脂綿などのような液体を吸収保持する材料に含浸し、肛門に挿入するというものである。具体的には、直径1cm程度にカットした脱脂綿に本例の精製した竹酢液を0.25mg〜1mg含浸させ、排便後及び入浴後を目安に1日2回投与した。
(Dosage test)
An administration test to humans was conducted on the bamboo vinegar liquid purified by the above procedure.
The bamboo vinegar solution used was obtained by purifying the sample C described above to a benzpyrene concentration of 1 ppt or less.
As described above, the method of using the bamboo vinegar in this example is to impregnate a material that absorbs and holds a liquid such as absorbent cotton and insert it into the anus. Specifically, absorbent cotton cut into a diameter of about 1 cm was impregnated with 0.25 mg to 1 mg of the refined bamboo vinegar solution, and administered twice daily after defecation and after bathing.

[肺機能・肝機能」
表1は、前記の方法によって6ヶ月間投与を毎日継続し、分析機関である宮城県医師会健康センターで、投与開始前と6ヶ月投与継続後の、肝機能、腎機能などの数値を測定した結果である。
ここでは、それぞれの数値と改善が見られた比率を併記した。
[Lung function / liver function]
Table 1 shows daily measurements of liver function, kidney function, etc. before the start of administration and after 6 months of administration at Miyagi Medical Association Health Center, which is an analysis institution, every day for 6 months. It is the result.
Here, each numerical value and the rate of improvement are shown.

Figure 2011157350
Figure 2011157350

表1に示した数値から明らかなように、肺機能や腎機能を示す数値はいずれも、投与前よりも投与継続後の方が改善されていて、竹酢液投与の効果が認められる結果となった。   As is clear from the numerical values shown in Table 1, the numerical values indicating lung function and renal function are both improved after administration than before administration, and the results of the administration of bamboo vinegar are recognized. became.

[爪水虫]
また、同様にして爪水虫に対する治療効果についても検討した。この場合は9ヶ月間の継続投与で効果が現れた。図1は、竹酢液投与前の爪水虫の状態を撮影した写真、図2は、竹酢液を4ヶ月間継続投与した後の爪水虫の状態を撮影した写真、図3は、竹酢液を4ヶ月間継続投与した後の爪水虫の状態を撮影した写真である。
これらに示した結果は、本例の治療剤による殺菌効果が、門脈を通過せず全身血流によって身体の末端まで到逮したためと解される。肝臓代謝の影響を受けず、初回通過効果を受けずに治療効果を奏するという効果も有する。
[Nail athlete's foot]
Similarly, the therapeutic effect on nail fungus was also examined. In this case, the effect appeared after continuous administration for 9 months. FIG. 1 is a photograph of the state of nail athlete's foot before administration of bamboo vinegar, FIG. 2 is a photograph of the condition of nail athlete's foot after continuous administration of bamboo vinegar for 4 months, and FIG. 3 is bamboo vinegar. It is the photograph which image | photographed the state of the nail fungus after continuously administering a liquid for 4 months.
The results shown in these figures are considered to be because the bactericidal effect of the therapeutic agent of this example reached the end of the body by the whole body blood flow without passing through the portal vein. It also has the effect of producing a therapeutic effect without being affected by liver metabolism and without receiving the first-pass effect.

また、前記のように竹酢液を投与すると、排便時の肛門、下腹部に爽快感を自覚でき、腹痛や腹部のゴロゴした感じがなくなり、大便の硬さも排便に支障のない状態を維持でき、竹酢液の殺菌作用が効を奏していることが窺える。そして投与前に肛門周辺に痛みや痒みを感じていた場舎は、それらの症状も解消し、痔に対する治療効果も認められた。   In addition, when bamboo vinegar is administered as described above, the anus and lower abdomen during a stool can be refreshed, abdominal pain and abdominal feeling disappeared, and the hardness of the stool can maintain a state that does not interfere with the stool. It can be seen that the bactericidal action of bamboo vinegar is effective. The hall that felt pain and itching around the anus before administration resolved those symptoms, and a therapeutic effect on the fistula was also observed.

以上に説明したように、本発明によれば、竹酢液の肛門からの投与による、爪水虫などに対する効果が大きく、副作用が少ない治療剤を提供することができ、医療費低減や健康増進に寄与するところは極めて大きく、有用である。   As described above, according to the present invention, it is possible to provide a therapeutic agent that has a large effect on nail athlete's foot by administration of bamboo vinegar from the anus and has few side effects. The contribution is extremely large and useful.

[大腸ポリープ検査]
図9から図12に腸に対する影響を調べた。
図9に投与前における腸の内視鏡写真を示す。図10に検査箇所をしめす。1−8が検査箇所であり、図9に示すように、1−4の矢印で示す位置にポリープが見出されている。
6月間の上記投与後における検査結果を図11に示す。なお、検査箇所は図12における1−4である。図11に示すように、1−4の箇所にポリープは見当たらなかった。
[Colon polyp examination]
The effect on the intestine was examined in FIGS.
FIG. 9 shows an endoscopic photograph of the intestine before administration. FIG. 10 shows the inspection location. 1-8 is an inspection location, and a polyp is found at a position indicated by an arrow 1-4 as shown in FIG.
The test results after the above administration for 6 months are shown in FIG. The inspection location is 1-4 in FIG. As shown in FIG. 11, no polyp was found at 1-4.

Claims (5)

ベンツピレンの含有量が1ppt(重量ppt、以下同じ)以下の木酢液からなり、肛門から投与して用いることを特徴とする液状組成物。 A liquid composition comprising a vinegar solution of benzpyrene having a content of 1 ppt (weight ppt, the same shall apply hereinafter) or less, and being administered through the anus. 大腸内の回虫、ヘリコバクター・ピロリを死滅させるとともに、インスリン受容体の抗体を消滅させる糖尿病治療剤としての用途に用いる請求項1記載の液状組成物。 The liquid composition according to claim 1, which is used for use as a therapeutic agent for diabetes which kills roundworms and Helicobacter pylori in the large intestine and extinguishes insulin receptor antibodies. 木酢液の殺菌作用を、直接患部に作用させる痔の治療剤としての用途に用いる請求項1記載の液状組成物。 The liquid composition of Claim 1 used for the use as a therapeutic agent of the hemorrhoid which makes the bactericidal action of wood vinegar act on an affected part directly. 木酢液の殺菌作用を、門脈を通過せず血流に付与する爪水虫又は大腸ポリープの治療剤としての用途に用いる請求項1記載の液状組成物。 The liquid composition according to claim 1, which is used as a therapeutic agent for nail athlete's foot or colon polyp which imparts the bactericidal action of wood vinegar to the bloodstream without passing through the portal vein. 木酢液は竹酢液である請求項1ないし4のいずれか1項記載の液状組成物。 The liquid composition according to any one of claims 1 to 4, wherein the wood vinegar is bamboo vinegar.
JP2011001498A 2010-01-06 2011-01-06 Liquid composition Expired - Fee Related JP4920788B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011001498A JP4920788B2 (en) 2010-01-06 2011-01-06 Liquid composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010014745 2010-01-06
JP2010014745 2010-01-06
JP2011001498A JP4920788B2 (en) 2010-01-06 2011-01-06 Liquid composition

Publications (2)

Publication Number Publication Date
JP2011157350A true JP2011157350A (en) 2011-08-18
JP4920788B2 JP4920788B2 (en) 2012-04-18

Family

ID=44589632

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011001498A Expired - Fee Related JP4920788B2 (en) 2010-01-06 2011-01-06 Liquid composition

Country Status (1)

Country Link
JP (1) JP4920788B2 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012144584A (en) * 2011-01-06 2012-08-02 Yasuhiro Takano Pyrolignous acid and method for producing the same
CN104173621A (en) * 2014-09-01 2014-12-03 扬中牧乐药业有限公司 Compound preparation for prevention and control of gill rot of grass carps
CN104274671A (en) * 2014-09-15 2015-01-14 扬中牧乐药业有限公司 Chinese herb medicinal preparation for preventing and treating capillariosis of finless eels
CN105288469A (en) * 2015-10-28 2016-02-03 葛善文 Traditional Chinese medicine composition for treating hemorrhagic hemorrhoids, preparing method thereof and application thereof
CN105748486A (en) * 2016-04-20 2016-07-13 辛集市远翔环保能源科技有限公司 Haemorrhoids treatment composition
WO2023153649A1 (en) * 2022-02-08 2023-08-17 서울대학교병원 Composition containing helicobacter pylori eradication agent for preventing or treating diabetes

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02145524A (en) * 1988-11-29 1990-06-05 Katsumi Nagata Production of raw material of drug obtained from pyroligneous acid
JPH10306034A (en) * 1997-05-08 1998-11-17 Nippon Mokutan Kk Cutaneous remedy
JP2002212093A (en) * 2001-01-24 2002-07-31 Seiji Hirai Skin care pyroligneous acid liquid composition and sheet for adhering to skin
JP2004141141A (en) * 2002-08-27 2004-05-20 Yamanashi Yagen Kk Method for producing bamboo pyroligneous liquid and food containing the same
JP2004300419A (en) * 2003-03-19 2004-10-28 Jgc Corp Method for manufacturing modified filtrate and modified filtrate obtained by this manufacturing method
JP2005015722A (en) * 2003-06-27 2005-01-20 Gifu Prefecture Wood or bamboo vinegar, and method and apparatus for manufacturing the same
JP2005179245A (en) * 2003-12-18 2005-07-07 Yamanashi Yagen Kk Antiallergic composition containing wood vinegar/bamboo vinegar distillate
JP2005200393A (en) * 2004-01-16 2005-07-28 Polysis:Kk Creamy composition of bamboo vinegar (chikusaku-eki)
JP2005255865A (en) * 2004-03-12 2005-09-22 Odaka Ringyo:Kk Method for producing highly purified pyroligneous acid

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02145524A (en) * 1988-11-29 1990-06-05 Katsumi Nagata Production of raw material of drug obtained from pyroligneous acid
JPH10306034A (en) * 1997-05-08 1998-11-17 Nippon Mokutan Kk Cutaneous remedy
JP2002212093A (en) * 2001-01-24 2002-07-31 Seiji Hirai Skin care pyroligneous acid liquid composition and sheet for adhering to skin
JP2004141141A (en) * 2002-08-27 2004-05-20 Yamanashi Yagen Kk Method for producing bamboo pyroligneous liquid and food containing the same
JP2004300419A (en) * 2003-03-19 2004-10-28 Jgc Corp Method for manufacturing modified filtrate and modified filtrate obtained by this manufacturing method
JP2005015722A (en) * 2003-06-27 2005-01-20 Gifu Prefecture Wood or bamboo vinegar, and method and apparatus for manufacturing the same
JP2005179245A (en) * 2003-12-18 2005-07-07 Yamanashi Yagen Kk Antiallergic composition containing wood vinegar/bamboo vinegar distillate
JP2005200393A (en) * 2004-01-16 2005-07-28 Polysis:Kk Creamy composition of bamboo vinegar (chikusaku-eki)
JP2005255865A (en) * 2004-03-12 2005-09-22 Odaka Ringyo:Kk Method for producing highly purified pyroligneous acid

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012144584A (en) * 2011-01-06 2012-08-02 Yasuhiro Takano Pyrolignous acid and method for producing the same
CN104173621A (en) * 2014-09-01 2014-12-03 扬中牧乐药业有限公司 Compound preparation for prevention and control of gill rot of grass carps
CN104274671A (en) * 2014-09-15 2015-01-14 扬中牧乐药业有限公司 Chinese herb medicinal preparation for preventing and treating capillariosis of finless eels
CN105288469A (en) * 2015-10-28 2016-02-03 葛善文 Traditional Chinese medicine composition for treating hemorrhagic hemorrhoids, preparing method thereof and application thereof
CN105748486A (en) * 2016-04-20 2016-07-13 辛集市远翔环保能源科技有限公司 Haemorrhoids treatment composition
WO2023153649A1 (en) * 2022-02-08 2023-08-17 서울대학교병원 Composition containing helicobacter pylori eradication agent for preventing or treating diabetes

Also Published As

Publication number Publication date
JP4920788B2 (en) 2012-04-18

Similar Documents

Publication Publication Date Title
JP4920788B2 (en) Liquid composition
Bocci OZONE.
Fukumoto et al. Flavor components of monoterpenes in citrus essential oils enhance the release of monoamines from rat brain slices
AU664492B2 (en) Method and composition for treating inflammatory bowel disorders
JP2017533276A (en) Methods for treating cognitive decline
KR101281470B1 (en) Compositions for skin external comprising castor oil extracted hexane, undecylenic acid, propyl alcohol, propylene glycol and water for prevention or treatment of tinea pedis
Zainalabidin et al. Hibiscus sabdariffa Linn.(Roselle) protects against nicotine-induced heart damage in rats
Benito et al. Remifentanil and cyclooxygenase inhibitors interactions in the minimum alveolar concentration of sevoflurane in the rat
CN100341529C (en) Combination of Tibet medicine of containing salt and possessing medicinal effect health care, and preparation metohd
US7374772B2 (en) Topical antifungal treatment
CN101099857A (en) Compound Chinese and Western medicine preparation for treating ringworm of hand or foot and onychomycosis and preparation method and quality control method thereof
EA200501057A1 (en) PHARMACEUTICAL COMBINATION FOR PREVENTION OR THERAPEUTIC TREATMENT OF CARDIOVASCULAR, CARDI-PULMONARY, PULMONARY OR KIDNEY DISEASES
Carubbi et al. Skin, inflammation and sulfurous waters: What is known, what is believed
DiGeronimo et al. Sedation and anesthesia of amphibians
CN106687113A (en) Omega-3 compositions, dosage forms, and methods of use
JP6263707B2 (en) How to treat hypercholesterolemia
Lindström et al. The selective 5-hydroxytryptamine 1A antagonist, AZD7371 [3 (R)-(N, N-dicyclobutylamino)-8-fluoro-3, 4-dihydro-2H-1-benzopyran-5-carboxamide (R, R)-tartrate monohydrate](robalzotan tartrate monohydrate), inhibits visceral pain-related visceromotor, but not autonomic cardiovascular, responses to colorectal distension in rats
Miyamoto et al. Phosphatidylinositol 3-kinase inhibition induces vasodilator effect of sevoflurane via reduction of Rho kinase activity
LeBaron et al. Effects of an H2-infused, Nitric Oxide-Producing Functional Beverage on Exercise and Cognitive Performance
JP2009114083A (en) Antibacterial agent and external preparation for skin
Kim et al. Carthami flos regulates gastrointestinal motility functions
RU2455019C1 (en) Herbal tea for treating constipations in patients suffering cerebrovascular diseases
US20160030499A1 (en) Adaptogenic Compositions And Method For Production Thereof
Crowley et al. Hypoventilation, cardiac dysrhythmia, and cardiac arrest following acute Brunfelsia species (Yesterday, today, tomorrow) intoxication in a dog
Eltayb et al. Topiramate augments the antipsychotic-like effect and cortical dopamine output of raclopride

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110301

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20110301

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20110324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110330

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110530

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110824

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111124

A911 Transfer of reconsideration by examiner before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20120113

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20120125

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20120201

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20150210

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees